Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
In Partnership With:
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.
In this episode, Dr Lunning sat down with Sarah Rutherford, MD, to discuss the phase 3 SWOG S1826/ECHELON-1 trial (NCT03907488) of brentuximab vedotin (Adcetris; BV) plus doxorubicin, vinblastine, and dacarbazine (AVD) in older patients with Hodgkin lymphoma. Dr Rutherford is an assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.
Drs Lunning and Rutherford highlighted key findings from the ECHELON-1 trial in the cohort of patients over 60 years of age, differentiating factors of Hodgkin lymphoma in younger vs older patients, the importance of determining an optimal and tolerable balance of checkpoint inhibitors plus chemotherapy, and more.
